Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)

LONDON, February 19 /PRNewswire-FirstCall/ -- - Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portel...

Widespread Commercialisation Of Human Organ Donation In China

Shocking reports of organs from executed prisoners being sold to foreigners for human transplantation purposes in China has raised much controversy and confusion. Chinese health officials, who have been passive// about the issue for a long time, have admitted about the widespread prevalence of such...

Nycomed Announces FDA Filing for Daxas(R) in COPD

...ing, which follows the submission of Daxas to the EMEA in May, is another important step for Daxas in the key US market. Discussions with potential US commercialisation partners are now well advanced." COPD remains a significant area of unmet medical need. It is a progressive and irreversible lung disease res...

Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office

... core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading r...search and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a ...

Alimentary Health's Probiotic Technology Launched Nationwide in the US

...iotic technology trademarked by P&G as Bifantis(R). Bifantis was developed by Alimentary Health, a global leader in the discovery, development and commercialisation of proprietary probiotic and pharmabiotic treatments for GI disorders and other inflammatory conditions, in partnership with P&G. Alimentary Healt...

GSK Extends Strategic Collaboration with Aspen

...sed by other parties. Activities combined in Sub-Saharan Africa Under the terms of the agreement, GSK and Aspen will collaborate on the commercialisation of their current and future product portfolios in Sub-Saharan Africa (excluding South Africa). The vast majority of combined current sales in this reg...

Starpharma and Elanco Sign Agreement

...tralia, May 11 /PRNewswire/ -- Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company. The parties will collaborate to develop ne...

Zebrafish offer clues to treatments for motor neurone disease

...so have implications for treating spinal cord injuries following accidents. The research team is the first to benefit from the Edinburgh BioQuarter commercialisation initiative, funded by the University of Edinburgh and Scottish Enterprise, to assist translating research into therapies. Researchers have also recei...

Progen Receives Nasdaq Notice Regarding Board Composition

...independent Chairman. About Progen Progen Pharmaceuticals Limited is a biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and devel...

GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company

...YSE: PFE ) today announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialisation of HIV medicines. The new HIV business will be more sustainable and broader in scope than either company's individually, and will hold a 19% share of ...

Commercialisation in Medical Technology

Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930

LAUSANNE, Switzerland and WOBURN, Massachusetts, August 4 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Mercury Therapeutics, Inc. (Mercury), a ...

Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237

...eive up to $172.5 million for achieving pre-agreed clinical, regulatory and commercialisation targets for both the monotherapy and combination product. These potential m...king statements", including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's or Sosei's actual results to...

Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies

...sed upfront payment and will be eligible for up to a total of $370m (GBP244m) upon the achievement of specified discovery, development, regulatory and commercialisation milestones. In addition to the upfront and milestone payments, OBT will receive double-digit royalties on sales of any product that it develops...

Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding

...ances from the Walloon Region General Directorate for Economy, Employment & Research. These funds, which bear no interest, become repayable on the commercialisation of C-Cure. Christian Homsy, CEO of Cardio3 BioSciences commenting on today's announcement said, "Our ability to raise this level of funding in ...

Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline

...ment, Biotica receives an initial cash payment, and is eligible to receive up to GBP86 million per compound in success-based development, approval and commercialisation milestone payments, as well as tiered royalties on net sales of resulting products. In addition, GSK has made an up front equity investment in a first...

Cambridge Laboratories Announces Approval of Tetrabenazine in Spain

...oratories (Ireland) Limited Cambridge is a fast growing, dynamic and entrepreneurial pharmaceutical company with extensive product development and commercialisation expertise focused on innovative products to treat diseases of the central nervous system. Cambridge has an exciting portfolio of products, both on the...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

.../ -- Stem Cell Sciences plc (AIM: STEM, ASX: STC), a company focused on the commercialisation of stem cells and stem cell technologies, notes that a paper describing a t...o SCS' strong portfolio of intellectual property around the development and commercialisation of stem cell technologies. The key step as described in the PLoS publicat...

Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008

...opharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulator...

NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium

... for achieving pre-agreed clinical, regulatory and commercialisation targets for both the monotherapy and combination p...ng statements about the discovery, development and commercialisation of products. Various risks may cause Sosei's or Ve... to conduct research and development and to expand commercialisation activities; and product initiatives by competitors...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

...opharmaceutical company headquartered in Reinach, Switzerland with operations in Switzerland and the USA. It focuses on the discovery, development and commercialisation of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulator...

Commercialisation in Biological News

CSIRO deal to commercialize 'artificial gut'

...nally developed to test the properties of new grains being developed by the Flagship. Dr Bruce Lee, Director of the Food Futures Flagship, said this commercialisation agreement will help address the growing global demand for foods with defined health benefits through low GI and higher fibre content particularly res...

Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB

...significant deal for UCL Business. I am delighted that Ocera is licensing the technology from us. In Ocera, we have found the perfect development and commercialisation partner. They specialise in liver and gastrointestinal drug development and have a demonstrated track record. I am excited to enter this relationshi...

Commercial yeasts upgraded with an enzyme for biofuel production

...s normally present within the yeast cells. The researchers have recently filed a patent application for their process. "This is a break-through in the commercialisation of cellulosic ethanol", comments Boles. Boles says: "We have successfully demonstrated the conversion of waste sugars into ethanol. However, ethano...

Lab test for allergy scoops national

... in their second year, the Da Vinci Awards, which are run through Loughborough University, recognise collaborative projects that lead to the potential commercialisation of healthcare innovations to save lives and improve services to patients. Dr Franco Falcone, Associate Professor in The University of Nottingham's ...

University success at national engineering awards

...cs. Susan Huxtable, Director of Technology Transfer says: "The University of Nottingham has an excellent track record for generation and successful commercialisation of new ideas and an equally good track record for working in collaboration with industry. We are delighted to have won two categories of the Engineer ...

Genetic data promises new future for kiwi fruit

...kiwifruit exclusively for ZESPRI and the New Zealand kiwifruit industry. It is a relationship that has already seen the breeding and highly successful commercialisation of ZESPRI GOLD kiwifruit and now looks poised to deliver more exciting fruit to the marketplace." ZESPRI New Products Innovation Leader Bryan Parke...

Scientists aim to boost world energy supplies -- with microbes!

...chnologies International's company creation division, where Profero Energy is based. University Technologies International is the technology transfer, commercialisation and incubation centre at the University of Calgary Robin Lockwood, Head of Commercial Development at Newcastle University, said: 'This groundbreakin...

Global deal fuels QUT's world-changing research

...t is expected to lead to an expanded 10-year collaboration. QUT Vice-Chancellor Professor Peter Coaldrake said the landmark deal, brokered by QUT's commercialisation company, qutbluebox, would provide the university with a significant global stake in the crucial field of biofuels research. "This collaboration i...

Taking the wrinkles out of motoneuronal disease

...on delivery system that could change our way of treating motoneuronal diseases." Dr Meunier's innovative research caught the attention of UQ's main commercialisation company, UniQuest Pty Ltd, which runs the annual Trailblazer competition. UniQuest Managing Director David Henderson said the Trailblazer judges we...

Delft water-purification method promises radical improvement

...aerobic granular sludge technology is very promising, and has been nominated for the Dutch Process Innovation Award 2006. The technology is now in the commercialisation phase. In the coming years, De Kreuk will continue to contribute to the project's trajectory as a Delft researcher. DHV is currently negotiating with ...

Commercialisation in Biological Technology

Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours

LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Moffitt Cancer Center (Moffitt), a non-profit Fl...

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully...

Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))

TOKYO, October 22 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a binding letter of agreement with ASKA Pharmaceuticals Co., Ltd. ...

Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment

MONTREAL, Aug. 5 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces today that it has reached an understanding with a fully integrated, U.S.-based, biotechnology company with respect to the development and global commercialization of several biopharmaceutical...

Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic

...s, announce the signature of an exclusive agreement for the development and commercialisation of Debio 0929, an antibody targeting a G protein-coupled receptor (GPCR), t...will grant Debiopharm a worldwide exclusive licence for the development and commercialisation of the antibody. MSM will retain marketing rights for Russia, Ukraine and s...

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

...ependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products. About QRxPhar...nical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) diso...

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

...of Concept") for four viral targets, at which point GlaxoSmithKline will have an exclusive option to license each compound for further development and commercialisation on a worldwide basis. Presently GSK has selected one viral disease target and Santaris Pharma has identified several strong drug candidates against th...

Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency

... core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading r...search and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a ...

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

...Senior Vice President for Worldwide Business Development. Dr. Greig also serves on the boards of Genocea Biosciences and the Edinburgh BioQuarter commercialisation Advisory Group, and is a member of the Imperial College Innovations Healthcare Advisory Board and a board observer for Anaphore, Inc. He holds a Ph.D...

Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates

...evelop its drug candidates until significant value has been created and proof of principle in man has been shown. For further clinical development and commercialisation of the products, Clavis Pharma will enter into strategic partnerships with established pharmaceutical or biotech companies. The company's product port...